Linked Life Data

10786659

Source:http://linkedlifedata.com/resource/pubmed/id/10786659

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2000-6-21
pubmed:abstractText
During the past decade, investigators have evaluated the role of hematopoietic growth factors as cytokines that could potentiate the cytotoxic action of certain chemotherapeutic agents when administered simultaneously with induction therapy. Such cytokines included granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, interleukin 3, and stem cell factor. Phase I and II studies have confirmed a significant biologic activity of such priming therapy, and the aggregate of subsequent controlled studies have also established the safety of such manipulations. However, despite the plethora of clinical trials, data regarding clinical efficacy remain uncertain. It is fair to say that little progress in our clinical understanding has occurred during the past 24 months and at the present time, the concurrent use of growth factors with chemotherapy, as a method of enhancing the antileukemic action of cytotoxic therapy, remains very investigational.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1065-6251
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
197-202
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Concurrent use of growth factors and chemotherapy in acute leukemia.
pubmed:affiliation
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel. rowe@jimmy.harvard.edu
pubmed:publicationType
Journal Article, Review